DAX24.025 +1,0%Est505.835 +1,1%MSCI World4.343 -0,1%Top 10 Crypto9,2600 +3,4%Nas22.517 -1,0%Bitcoin60.955 +3,6%Euro1,1636 +0,2%Öl81,76 -0,2%Gold5.172 +1,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
freenet A0Z2ZZ AIXTRON A0WMPJ E.ON ENAG99 Münchener Rückversicherungs-Gesellschaft 843002 Heidelberg Materials 604700 Tesla A1CX3T Vonovia A1ML7J BioNTech (ADRs) A2PSR2 NEL ASA A0B733 AMD (Advanced Micro Devices) 863186 RWE 703712 Airbus 938914 Rolls-Royce A1H81L TKMS thyssenkrupp Marine Systems TKMS00 Micron Technology 869020
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach Kursrutsch: DAX auf Erholungskurs -- 24.000er-Marke zurückerobert -- adidas plant Milliardenrückkäufe -- Bayer mit Milliardenverlust -- Bitcoin, Gasaktien, Continental, CrowdStrike im Fokus
Top News
Bayer-Aktie unter Druck nach weiterem Milliardenverlust - Operativ etwas besser als gedacht Bayer-Aktie unter Druck nach weiterem Milliardenverlust - Operativ etwas besser als gedacht
Barclays Capital verleiht Brenntag SE-Aktie Equal Weight in jüngster Analyse Barclays Capital verleiht Brenntag SE-Aktie Equal Weight in jüngster Analyse
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Kodiak Sciences Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
22,46 EUR -0,16 EUR -0,71 %
STU
26,65 USD -0,71 USD -2,58 %
vorbörslich
BTT
finanzen.net zero
Kodiak Sciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.1,44 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2N6P0

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS50015M1099

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolKOD

Kodiak Sciences Aktien News

DatumMeistgelesen
PR NewswireKodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
PR NewswireKodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
PR NewswireKodiak Sciences to Present at Upcoming Investor Conferences
Wer­bungKodiak Sciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireFollow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 ...
PR NewswireNew data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
PR NewswireKodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)
PR NewswireKodiak Sciences to Present at American Chemical Society Fall 2025
PR NewswireKodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results
PR NewswireKodiak Sciences to Host Investor R&D Day on July 16, 2025
PR NewswireKodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society
PR NewswireKodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
PR NewswireKodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
PR NewswireKodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases
PR NewswireKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
PR NewswireKodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
PR NewswireKodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
PR NewswireKodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireKodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results
PR NewswireKodiak Sciences to Participate in Upcoming Investor Conferences
PR NewswireKodiak Sciences to Present at Innovate Retina 2024
PR NewswireKodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time
PR NewswireKodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City
PR NewswireKodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results
PR NewswireKodiak Sciences to Present at Upcoming Investor and Clinical Conferences
PR NewswireKodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
PR NewswireKodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
PR NewswireKodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Co...
PR NewswireKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
PR NewswireKodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
PR NewswireKodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
PR NewswireKodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireKodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
PR NewswireKodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
PR NewswireKodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regul...
PR NewswireKODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY AN...
PR NewswireKodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
PR NewswireKodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
PR NewswireNew one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vei...
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
PR NewswireKodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

Kodiak Sciences News

Kodiak Sciences News: auf dieser Seite finden Sie alle Kodiak Sciences News und Nachrichten zur Kodiak Sciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Kodiak Sciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Kodiak Sciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.